Evidence map›Paper›PMID 33731765›Full record

ArticleScientific reports2021

The association of genetic polymorphisms with neuroconnectivity in breast cancer patients.

Rebecca A Harrison, Vikram Rao, Shelli R Kesler

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Seeing through "brain fog": neuroimaging assessment and imaging biomarkers for cancer-related cognitive impairments.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024
    Review
  14. Article
  15. Review
  16. Article
  17. [Cognitive deficits with chemotherapy in women with breast cancer: a bibliographic revisión]Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina) · 2023
    Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Rebecca A HarrisonDepartment of Neuro-Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 431, Houston, TX, 77030, USA. RAHarrison@mdanderson.orga.
Vikram RaoCancer Neuroscience Laboratory, School of Nursing, University of Texas at Austin, Austin, TX, 78712, USA.
Shelli R KeslerCancer Neuroscience Laboratory, School of Nursing, University of Texas at Austin, Austin, TX, 78712, USA.
Livestrong Foundation · USThe University of Texas at Austin · USThe University of Texas MD Anderson Cancer Center · US

Funding

Very-long Term Neurocognitive Outcomes in Breast Cancer Survivors (ProbC2)R01CA172145 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI KESLER, SHELLI R, PALESH, OXANA G · 2012 to 2024
$3.3M
Predicting Long-Term Chemotherapy-Related Cognitive ImpairmentR01CA226080 · NCI · UNIVERSITY OF TEXAS AT AUSTIN · PI KESLER, SHELLI R, PALESH, OXANA G · 2019 to 2024
$3.1M
Assessment and Treatment of Cognitive Deficits in Breast CancerDP2OD004445 · OD · STANFORD UNIVERSITY · PI KESLER, SHELLI R · 2008 to 2008
$2.4M
NCI NIH HHS R01 CA172145NCI NIH HHS R01 CA226080NIH HHS DP2 OD004445
6 · The paper itself

Abstract

Genetic polymorphisms in select genes, including APOE (apolipoprotein E), COMT (Catechol-O-Methyltransferase), MDR1 (multi-drug resistance 1), BDNF (brain derived neurotrophic factor), and GST (glutathione-S-transferase), have been associated with vulnerability to cognitive impairment. In this study, we evaluated the relationship of these genetic variants to measures of brain health in patients with breast cancer, including neurocognitive testing and functional connectome analysis. Women with breast cancer (n = 83) and female healthy controls (n = 53) were evaluated. They underwent resting-state functional MRI scans and neurocognitive testing. Polymerase chain reaction (PCR) was performed on saliva samples to identify single nucleotide polymorphisms (SNPs) in candidate genes: APOE, COMT, MDR1, BDNF, and GST. Breast cancer patients treated with chemotherapy had slower processing speed (p = 0.04) and poorer reported executive function (p < 0.0001) than healthy controls. Those chemotherapy-treated patients that were APOE e4 carriers had significantly slower processing speed. A greater number of risk-related alleles was associated with poorer connectivity in the regions of the left cuneus and left calcarine. While breast cancer patients that are APOE e4 carriers may have a select vulnerability to processing speed impairments, other risk-related alleles were not found to influence cognitive test performance in this population. Conversely, regions of impaired functional connectivity appeared to be related to risk-related genetic polymorphisms in breast cancer patients. This suggests that a cancer patient's SNPs in candidate genes may influence the risk of neurotoxicity. Further study evaluating the impact of genotype on biomarkers of brain health in cancer survivors is warranted.

Indexed as

AdultAgedBiomarkers, TumorBreast NeoplasmsCognitive DysfunctionFemaleGenetic Predisposition to DiseaseHumansMiddle AgedPolymorphism, Single NucleotideBiomarkers, Tumor

Identifiers

PMID33731765
PMCPMC7971072
OpenAlexW3138359740

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.